Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

237.03 9.71 +4.27%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a P/E ratio of 62.6×. Over the past ten years it has ranged from 0.0× (March 2026) to 522× (June 2026); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/JAZZ/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Jazz Pharmaceuticals PLC P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/JAZZ/metrics/pe-ratio">Jazz Pharmaceuticals PLC (JAZZ) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	0.0×	—
FY2024	13.5×	(30.24%)
FY2023	19.4×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	38.3×	136.52%
FY2019	16.2×	(2.56%)
FY2018	16.6×	(1.68%)
FY2017	16.9×	(2.35%)
FY2016	17.3×	(33.75%)

Period	P/E ratio	Change
Sep 2026	63.6×	302.68%
Jun 2026	15.8×	(96.16%)
Mar 2026	411×	—
Dec 2025	0.0×	—
43 more quarters	Free account

Against its own ten years

Low 0.0× High 522×

Ten-year median 18.5×

Current reading's percentile 90

Company	P/E ratio
KYMR Kymera Therapeutics, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	n/m
SMMT Summit Therapeutics PLC compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
ASND Ascendis Pharma A/S compare	18.3×
EXEL Exelixis, Inc. compare	19.9×
HALO Halozyme Therapeutics, Inc. compare	29.5×
TECH Bio-Techne Corp compare	62.2×
JAZZ Jazz Pharmaceuticals PLC	62.6×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Jazz Pharmaceuticals PLC (JAZZ) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on JAZZ

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on JAZZ

Stockrow Weekly